TOP STORIES

• BUSINESS Hengrui to Apply for Sakigake Designation; Develop New Drugs Alongside Generics in Japan
  March 24, 2016

• ACADEMIA Positioning of Abraxane and Anti-PD-1 Antibodies Will Be Focus of Interest in Revised Guidelines for Gastric Cancer
  March 23, 2016

• BUSINESS Jitsubo Aims to Launch Peptide Generic Drugs Using Its Unique Technologies
  March 22, 2016

• ORGANIZATION FPMAJ Braced for Thorny Path Ahead Even If Sales Tax Postponed, Revenue Falls Would Weigh on Industry: Chief
  March 18, 2016

• ORGANIZATION Discuss Role of Drugs in Overall Social Security System: Full Interview with FPMAJ Pricing Affairs Chief
  March 18, 2016

• REGULATORY Whether to Draw Line between 15 Billion and 100 Billion Yen Sales Thresholds for Re-Pricing Will Hold Key: Kamoya, Nakai
  March 17, 2016

• ACADEMIA It’s Time to Discuss Restart of HPV Vaccine Promotion, Panel Chief Says as Personal View
  March 16, 2016

• REGULATORY Sales Thresholds for Re-Pricing Rule to Be Key Point of Future Discussions: MHLW Pharma Management Director
  March 15, 2016

• REGULATORY No Licensing Deal Clinched for First AMED-Backed Drug Seed
  March 14, 2016

• BUSINESS Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
  March 11, 2016

• ORGANIZATION “Huge-Seller” Re-Pricing Eroding Predictability of Japanese System: FPMAJ’s Kamoya
  March 10, 2016

• BUSINESS Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
  March 9, 2016

• BUSINESS Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
  March 8, 2016

• BUSINESS Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
  March 7, 2016

• REGULATORY Sovaldi, Harvoni Face 31.7% Price Cut under “Huge Seller” Re-Pricing: MHLW
  March 4, 2016

• REGULATORY FY2016 NHI Pricing Reform to Bring “1 Victory, 1 Defeat, 1 Draw” for Industry: MHLW Official
  March 3, 2016

• BUSINESS Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
  March 2, 2016

• BUSINESS Drug Wholesalers’ Inventory Margins Likely to Diminish for FY2016 Price Revision
  March 1, 2016

• BUSINESS PCSK9 Inhibitor Repatha Expected to Debut this Spring, with Competing Products to Follow
  February 29, 2016

• BUSINESS Torii to Expand Sales Force to 570 by FY2018; Will Actively Seek Acquisitions, Alliances
  February 26, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 173
• 174
• 175
• 176
• 177
• 178
• 179
• 180
• 181
• …
• Next ›
• 最終 »